Economic Overview
Global Economy1
The global economy remained stable in CY2025, growing by 3.3%, supported by sustained private investment and easing inflation. Growth divergence persisted, with emerging markets and developing economies expanding by 4.4%, compared to 1.7% in advanced economies. A relatively weaker US dollar and coordinated monetary conditions supported capital flows and demand in developing markets.
Global Economic Outlook
Global trade expansion is expected to moderate as the benefits of supply chain reconfiguration stabilise and the impact of tariffs gradually feed into end-market pricing. Chinas efforts to address excess capacity are likely to increase its focus on domestic demand while maintaining strong trade linkages across Asian supply chains.
Geopolitical uncertainty remains a key risk, requiring companies to maintain flexibility through diversified sourcing and regionalised supply chains.
Investment in artificial intelligence is expected to remain strong, supported by its demonstrated impact on productivity and operational efficiency. Its growing application in demand forecasting, inventory optimisation and process automation is improving cost control across industries.
Indian Economy2
India?s economy remained resilient in FY 2025-26, recording GDP growth of 7.7% despite external uncertainties3. Inflation moderated, supported primarily by stable food prices and improved supply conditions. This created room for the Reserve Bank of India to ease monetary policy, with a cumulative rate cut of 100 basis points to 5.25%, improving overall liquidity and credit conditions.
Manufacturing activity remained strong, with the Purchasing Manager?s Index (PMI) indicating sustained expansion, driven by healthy order flows and productivity improvements. Industrial production recovered during the year, supported by improved output in automobiles, basic metals and mining.
Consumption trends strengthened, with private final consumption expenditure increasing by over 7%. This was supported by a resurgence in rural demand and declining inflation. Policy measures, including GST rationalisation, also contributed to improved consumption patterns, particularly in urban markets.
Structural efforts to strengthen India?s innovation ecosystem continued. The government?s Research Development and Innovation (RDI) scheme, with an outlay of H 1 lakh Crore, is aimed at increasing private sector participation in advanced manufacturing and technology development.4
Indian Economic Outlook
Indias growth momentum is expected to remain stable. A gradual rebound in the manufacturing activity, along with ongoing structural reforms, is expected to help navigate external uncertainties.
Infrastructure investment remains a key driver. The Union Budget for FY 2026-27 provides for an 11.5% increase in capital expenditure to H12.22 lakh Crore, reinforcing the focus on long-term capacity creation and economic expansion.
Recent and proposed free trade agreements, including those with the European Union and New Zealand, are expected to improve market access for Indian exporters. These agreements are likely to support export growth and attract foreign investment, particularly in sectors such as pharmaceuticals.
Industry Overview
Global Pharmaceutical Industry5
Despite an evolving macroenvironment affecting the industry, the world?s prescription drug market has exhibited resilient performance in CY 2025. The industry witnessed sales worth $1.7 trillion based on list prices, registering a 10% year-on-year growth.
Global Medicine List Price Sales
This expansion was driven primarily by established drugs alongside continuous innovation. Next-generation treatments are supporting growth, including biologics, antibody drug conjugates, biosimilars, mRNA, peptides, cell and gene therapies. These therapies are forecasted to account for nearly 43% of the global pharmaceutical market by value.6
CAR-T Cell Therapies (CAR-Ts)
Representing the leading edge of personalised oncology, CAR-T therapies involve extracting a patient?s own T cells, genetically modifying them and re-infusing them to target and destroy malignant cells with exceptional precision.
In CY 2025, this modality generated $5.8 billion in sales, with projections reaching $8 billion by CY 2030.
In CY 2025, a total of 73 new active ingredients were introduced globally, exceeding the annual average of the past decade.
7
Global obesity medicine spending increased sharply between 2023 and 2024, driven by the adoption of innovative therapies. Obesity- related medicine spending is projected to increase by 201% between 2025 and 2029, representing a CAGR of 23-26% and an incremental market opportunity of approximately $50.7 billion. The base-case outlook estimates the global obesity medicines market at approximately $77 billion by 2029, while broader adoption and reimbursement expansion could support a higher market scenario of up to $118 billion. Growing awareness of metabolic health and increasing treatment penetration are expected to support sustained long-term demand for obesity therapies.Regional Analysis LATAM and Asia-Pacific
Growth across Latin America is expected to remain strong through 2029, supported by improving healthcare access, rising chronic disease prevalence and sustained pharmaceutical demand across key markets such as Brazil and Mexico. Alongside Asia- Pacific markets, the region is projected to record faster growth in medicine usage and spending compared to several developed economies. Over the past five years, global patient usage of medicines increased by 14%, driven in part by expanding healthcare access across China, Asia-Pacific and Latin America.
In Brazil, continued growth is supported by rising healthcare expenditure, expanding treatment access and increasing demand for chronic disease therapies. Meanwhile, Canada?s pharmaceutical market continues to evolve through pricing reforms, broader biosimilar adoption and changing healthcare delivery models aimed at improving system efficiency and managing public healthcare costs.
Southeast Asia
Across Southeast Asia, rising incomes and an expanding middle class are shifting consumer preferences towards more convenient, high-quality and personalised healthcare services. To meet this evolving demand, the Association of Southeast Asian Nations (ASEAN) is advancing its Pharmaceutical Regulatory Policy to harmonise regional standards, promote intra-bloc trade and reduce import reliance.
Within the region, specific markets are scaling rapidly. Indonesias pharmaceutical sector is expanding, supported by the world?s largest single-payer national health insurance system, while Vietnam and Thailand are leveraging robust research hospital networks to become premier clinical trial destinations. Concurrently, the Philippines has emerged as a leading market for international pharmaceutical firms seeking to establish regional presence.
United States
The U.S. pharmaceutical market is projected to grow at a CAGR of 3-6% on a net price basis through 2029, reflecting moderation compared to the stronger growth recorded over the previous five-year period. Despite the normalization in percentage growth, net medicine spending is still expected to increase substantially, rising from approximately $487 billion in 2024 to nearly $800 billion by 2029. Growth is expected to be driven by continued adoption of innovative therapies across oncology, immunology, neurology, obesity and diabetes treatment segments. At the same time, the industry is expected to witness increasing pressure from patent expiries and biosimilar competition, which are likely to intensify pricing pressures while creating opportunities for generic and lower-cost therapeutic alternatives.
Europe
Pharmaceutical spending across Europe is projected to increase by approximately $85 billion through 2029, supported by continued demand for innovative therapies as well as established branded treatments. Growth within the region is expected to be driven primarily by the EU4 markets and the UK, with increasing adoption of specialty medicines across oncology, immunology and rare disease therapies. In addition, Germany continues to demonstrate one of the fastest uptake rates for innovative pharmaceutical launches among major global markets, reflecting strong access to new therapies and a supportive commercial environment.
At the same time, the European pharmaceutical market continues to operate within a highly regulated pricing and reimbursement framework. Ongoing healthcare policy initiatives aimed at strengthening healthcare preparedness, accelerating clinical development and improving access to innovative medicines are expected to support long-term market expansion. However, continued pricing pressure from patent expiries, biosimilar competition and broader healthcare cost- containment measures across public healthcare systems may moderate overall market value growth over the forecast period.
South Africa*
South Africa?s pharmaceutical market is the largest and most mature in sub-Saharan Africa, valued at approximately USD 8.3 billion and projected to reach up to USD 12.4 billion by 2033. The market is expected to grow at a Compound Annual Growth Rate (CAGR) of 5.2% to 5.5%. Driven by cost containment and government mandates, it features a strong demand for generic drugs and a rapidly growing biologics sector. Conventional small-molecule drugs dominate, but biologics and biosimilars represent the fastest-growing segment. The high cost of patented drugs and single-exit pricing policies push strong utilization of generic medicines. High demand for treatments targeting HIV/AIDS, tuberculosis (TB), cancer, and lifestyle- related chronic diseases.
Outlook
Global medicine spending is projected to exceed $2.6 trillion over the next five years, growing at a CAGR of 5-8%. The US is expected to remain the largest contributor to global pharmaceutical expenditure.
The industry is focused on the fast-track approvals of novel therapies, especially personalised medicines. In terms of value, the oncology segment is expected to continue its lead in the market share. Further, a high growth rate in obesity and CNS drugs is anticipated to be another driving factor for market expansion.
Key Therapeutic Areas
^Oncology
Global oncology therapy has increased by 3% annually since 2019, largely driven by Pharmerging countries (per capita income < $30,000 and > $1Bn five-year pharma spend growth) and continued reliance on traditional chemotherapies. Alongside diabetes and obesity, oncology will drive absolute growth through 2029, with oncology and obesity forecasted to post double-digit CAGR. Global cancer medicine spending reached $252Bn in 2024, the highest among other therapy areas and is expected to reach $441Bn by 2029, with growth expected to moderate over time.
Cardiology8
The global cardiovascular drugs market is valued at approximately $155.96 billion in 2025, sustained by a significant patient population requiring long-term management. Increasing incidence of cardiac arrests and arrhythmias continues to expand demand. Growth is fundamentally linked to lifestyle shifts, including rising obesity, sedentary behaviour and changing diets, all contributing to higher cardiovascular disease prevalence. The market is transitioning from traditional blockbuster drugs to diversified, precision-focused portfolios, with increasing investments in, gene regulators, RNA-based therapies, antiinflammatory agents and integrated cardio-renal-metabolic care. It is projected to reach approximately $214.72 billion by 2034, growing at a steady CAGR of 3.62% from 2025 through 2034.
Diabetology
The global diabetes drugs market increased from $70.40 billion in 2024 to $75.09 billion in 2025, driven by the rising prevalence of diabetes, increasing obesity rates, sedentary lifestyles and expanding treatment access across developing markets. Advancements in treatment modalities and growing awareness around metabolic health continue to support sustained demand for diabetes therapies.
Endocrinology spending, particularly across diabetes and obesity treatment segments, is witnessing significant expansion driven by the rapid uptake of GLP-1 receptor agonists and other innovative therapies. Obesity medicine spending is projected to increase by 201 % between 2025 and 2029, supported by broader adoption of novel therapies, expanding clinical indications and improving reimbursement access. Increased usage of these therapies for obesity, cardiovascular risk reduction and sleep apnea management is expected to further strengthen long-term market growth.
The growing adoption of advanced diabetes and obesity therapies remains concentrated in the United States and other developed healthcare markets, where these treatments are increasingly being incorporated into earlier stages of disease management. However, pricing pressures and reimbursement dynamics continue to influence market expansion, as payers and healthcare systems evaluate the long-term affordability of premium therapies. Europe is also expected to witness continued growth, supported by increasing disease prevalence, healthcare access initiatives and ongoing research across injectables, oral therapies and biosimilars.
Indian Pharmaceutical Industry
India has established itself as the pharmacy of the world? by supplying affordable, -quality generics and vaccines to developing and regulated markets. It ranks 3rd globally by volume and 11th by value, with the market valued at $ 60 billion in 2025. India has the worlds highest number of US- FDA-compliant pharmaceutical manufacturing plants outside of the United States. Its API sector ranks as the third largest globally, supplying 57% of the API listed on the WHO Model List of Essential Medicines.10
The domestic industry is experiencing a structural transition toward a value-driven paradigm, expanding its footprint into complex generics, specialty medicines, biosimilars, and high-tech medical devices. Total pharmaceutical exports neared the $30.5 billion threshold, with approximately 50% of shipments directed to highly regulated markets like the United States and Europe.11
To reduce import dependence on critical bulk drugs and intermediates, the production capacity for 26 key APIs has been expanded under the central Production Linked Incentive (PLI) framework, attracting substantial domestic capital and generating extensive employment. Along with APIs, the H 15,000 crore outlay programme incentivises the commercialization of specialized therapeutic formulations, including advanced anti-cancer, anti-diabetic and cardiovascular drugs, moving Indian players up the global value chain.This manufacturing resilience is further augmented by a significant allocation in the Union Budget for the Department of Pharmaceuticals, which includes strategic fiscal outlays to promote centralized bulk drug and medical device parks across multiple states, positioning the country to capture higher-value segments in global healthcare commerce.
India is the largest supplier of generic medicines globally, accounting for-
20%
of global generics supply
8%
of the global API industry
Government Initiatives Production Linked Incentive Scheme
The PLI schemes by the Department of Pharmaceuticals are critical to boosting domestic manufacturing and reducing import dependence. They have already helped eliminate imports worth H 3,591 Crore across APIs, KSMs and DIs.
PLI Scheme for Pharmaceuticals
Focused on high-value biopharmaceuticals, complex generics and autoimmune medicines, the scheme has driven growth in sales, exports and employment. As of September 2025, investments stood at H 40,890 crore, leading to employment generation of around 97,000 jobs.
Research and Innovation
The Promotion of Research and Innovation in Pharma MedTech (PRIP) scheme aims to transition India from a generics-led to an innovation-driven economy. Seven Centres of Excellence have been established within the National Institutes of Pharmaceutical Education and Research (NIPER) with an expenditure of H 700 crores. The PRIP scheme provides financial support to MSMEs, startups and other industries working towards critical pharmaceutical and medtech research.
Biopharma Strategy for Healthcare Advancement through Knowledge, Technology and Innovation (SHAKTI) Announced in the Union Budget 2026-27, this scheme has an outlay of H 10,000 crores over the next five years. It aims to position India as a global biologics manufacturing hub, accelerating innovation and advanced biopharma capabilities.
Outlook
As the industry evolves, the focus is shifting from cost-driven manufacturing to innovation and R&D-driven growth. Strengthening intellectual property protection and regulatory transparency will be critical to attracting early-stage research and fostering innovation.
India?s policy framework continues to support domestic manufacturing of key starting materials (KSMs), drug intermediates and APIs, encouraging greater self-reliance and strengthening the pharmaceutical supply chain. Going forward, the industry is expected to maintain a steady growth trajectory, supported by favourable policies, rising healthcare demand and expanding manufacturing capabilities.
Crop Protection
The Indian crop protection chemicals market is projected to increase from $2.59 billion in 2025 to $2.71 billion in 2026, supported by a gradual shift towards organised players. Growth is driven by precision agriculture adoption, supportive government policies and an increasing focus on sustainable practices.
Primary growth drivers of the industry include Precision and sustainable agriculture: Expanding adoption of precision spraying technologies and a strategic transition toward Integrated Pest Management (IPM) protocols.
Risk mitigation: A heightened focus on managing agro-climatic risks, alongside regulatory tailwinds that favour the adoption of safer, modern chemistries.
Growth Headroom: Relatively low baseline per-hectare consumption signals significant potential for targeted volume and value expansion.
Global Supply Chain Realignment:
India?s emergence as a preferred international sourcing hub, supported by expanding technical capacities and global businesses diversifying their supply chains.
Structural Labour Dynamics:
Acute rural labour shortages are accelerating the transition towards chemical crop protection delivery as a more cost-effective and efficient alternative to manual application.
Production in FY 2025-26 reached 2,61,099 MT (up to February 2026), significantly exceeding the estimated demand of 74,266 MT, of which 42,000 MT is expected to be consumed during the Kharif 2026 season.
Government initiatives such as the $338 million Digital Agriculture Mission are accelerating demand for technologies compatible with drones and soil mapping. At the same time, structural challenges persist, including molecule bans across states, spurious chemicals and stringent residue regulations. Enforcement against counterfeit and substandard pesticides is strengthening, with closer coordination between central and state authorities.
Farmers are gradually shifting from conventional spraying to precision application techniques, improving input efficiency and aligning with environmental standards.
Indias foodgrain and oilseed scaling new heights
Outlook
The industry is estimated to reach $3.36 billion by 2031, exhibiting a CAGR of 4.45% from 2026 to 2031. Growth will be supported by farmer awareness, improved pest management practices and a stronger push towards biological pesticides and sustainable solutions.
Expanding access to innovative solutions, alongside targeted training and information services, will be essential for increasing productivity and securing food supplies. As global inventories stabilise and cropping cycles normalise, export demand is projected to recover. Indian manufacturers, leveraging their focus on cost-efficiency and portfolio diversification, are well- positioned to benefit from this market rebound. While regulatory scrutiny on residues is expected to intensify, adoption of digital spraying and chemigation systems will enhance efficiency and support long-term sectoral growth.
Company Overview
NATCO Pharma Ltd is an integrated, research-driven pharmaceutical company with over four decades of experience, focused on developing niche and complex molecules. Over the decades it has evolved to become one of the globally diversified pharmaceutical companies. The Company has also diversified into crop health sciences, offering agrochemical solutions in the Indian market. Its operations span Finished Dosage Formulations (FDF), Active Pharmaceutical Ingredients (API) and agrochemicals (technical and formulations). It is highly regarded as one of the pioneers in the Indian oncology therapeutic segment, where the company has launched many first-time generic cancer products. The API business specialises in multi-stage synthesis, high-potency APIs and peptides, largely for captive consumption.
The Company operates nine cutting-edge manufacturing facilities in India·seven for pharmaceuticals and two for agrochemicals, all compliant with various regulatory standards including USFDA, ANVISA, Health Canada and WHO. Formulation plants are situated in Dehradun (Himachal Pradesh), Kothur (Telangana), Nagarjuna Sagar (Telangana), Visakhapatnam (Andhra Pradesh) and Guwahati (Assam); API units are established in Mekaguda (Telangana) and Manali (Tamil Nadu) while the agrochemical production facilities are in Attivaram (Andhra Pradesh). It has a wide range of formulations portfolio includes capsules, injections, tablets and other dosage forms addressing various therapeutic areas such as Oncology, Neurology, Gastroenterology, Cardiology, Diabetes and others.
NATCO has a presence in over 50 countries, with major markets including the US, India, Canada and Brazil, supported by 13 subsidiaries/step-down subsidiaries and an Associate and strategic alliances across regions such as Southeast Asia, LATAM and the Middle East.
A major growth pillar is its R&D, with annual investments of H 4,086 million (FY 2025-26) and a planned allocation of 6-8% of revenues toward future innovation. The Company focuses on low-competition, high-complexity molecules, leveraging organic expansion strategies.
The formulation business, especially exports, accounts for the majority of revenues, while the APIs segment provides backward integration through cutting-edge manufacturing capabilities. In agrochemicals, the Crop Health Sciences division has established a strong position with CTPR & its combination products in India, well supported by the herbicides and growth promoter products in the portfolio.
NATCO is committed to maintain cGMP standards across its facilities and endeavours to keep with the evolving regulatory landscape.
On November 11,2025, NATCO Pharma South Africa Proprietary Limited ("NPSA") acquired 34.88% of Adcock Ingram Holdings Proprietary Limited ("Adcock Ingram"). Pursuant to this action, Adcock Ingram got delisted. Before delisting, NATCO Pharma Limited and NATCO Pharma (Canada) Inc. already held 0.12% and 0.75% of Adcock Ingram respectively. On a consolidated basis, NATCO ultimately owned 35.75% of Adcock Ingram. Later on in July 2026, NPSA acquired an additional shareholding of 13.25% of Adcock Ingram resulting in ultimate ownership of shareholding of 49% by NATCO in Adcock Ingram on a consolidated basis.
Segment-wise Performance
The Company operates through two primary segments· Pharmaceuticals and Agrochemicals. The pharmaceutical business serves as the main revenue driver, led by export formulations, followed by domestic formulations, Active Pharmaceutical Ingredients (APIs) and Agrochemicals.
The Company has established a notable global footprint, shipping formulation products to over fifty countries. The United States is the largest revenue contributor, followed by India, Canada and Brazil.
The API division is strategic in nature in order to cater to captive consumption and to ensure uninterrupted supply of products. It also sells to global pharmaceutical companies in USA, Brazil, Europe and India.
Leveraging proficiency in organic chemistry and the ability to target niche molecules, the company diversified into the Crop protection business. The product portfolio includes a range of quality pesticides, insecticides, bio-stimulants, and growth promoters designed for the safe and efficient management of pests, insects, diseases and weeds across various crops. The Company remains focused on providing greener and cleaner solutions to farmers to enhance crop outputs.
Pharmaceutical Segment
The domestic pharmaceutical business is organised into four specialised Divisions:
Oncology Pharma Specialty, Cardiology, Diabetology. These divisions are designed to address critical therapeutic areas through innovation, affordability, and quality, thereby improving patient benefits with advanced treatments.
Oncology
As a pioneer in oncology targeted therapy. The portfolio includes treatments for solid tumours and hemato-oncology. The current pipeline features molecules for various malignancies, including liver, lung and breast cancers.
The Company?s oncology products are manufactured in state- of-the-art facilities certified by major international regulatory authorities. This commitment to quality and reliability has earned the trust of oncologists, leading medical centres and the broader healthcare community.
Pharma Specialty
Under pharma specialty two divisions have been created. Dynami and Hygeia.
Dynami
Dynami business unit focuses on the anti-infectives segment, covering a comprehensive portfolio of Antibacterials, Antifungals, Antivirals.
The division engages with key specialists, including Infectious Disease experts, Intensivists, Pulmonologists, and Bone Marrow Transplant (BMT) physicians.
Natco is actively investing in building a future-ready portfolio to address emerging challenges in infectious diseases and antimicrobial resistance.
Hygeia
The division also caters to multiple specialties, including Gastroenterology, Hepatology, Rheumatology, Orthopaedics, Paediatric Neurology and critical care.
Key milestones in FY 25-26 include launch of Risdiplam for Spinal Muscular Atrophy (SMA), significantly improving medicine access in India.
The orthopaedics portfolio includes leading oral and injectable bisphosphonate therapies, which were first-to-market in their categories. In gastro-hepatology, NATCO is a dominant player in Hepatitis-B and Hepatitis-C treatments in India, with the Velpanat brand (Sofosbuvir and combination) being a high- performing product.
Cardiology
Established in 2017, the Cardiology division focuses on making specialty cardiovascular therapies widely accessible and affordable. The portfolio includes Antihypertensives, Antiplatelets, Novel Oral Anticoagulants
NATCO has achieved first-to-market status for key molecules such as Apixaban, Dabigatran. The division continues to expand its offerings with a focus on innovative and cost- effective treatment options for cardiovascular diseases.
Diabetology
NATCOs Diabetology segment offers a comprehensive range of therapies for diabetes management, including DPP-4 inhibitors, SGLT2 inhibitors. The Company is the first Indian generic manufacturer to launch Semaglutide injection for Type 2 Diabetes Mellitus, available in both injection and pen delivery formats. Natco remains committed to strengthening this segment through development of next-generation therapies, with a focus on patient-centric innovation
NATCO Pharma?s India business is anchored in Therapeutic leadership across specialty segments, First-to-market innovations, High-quality manufacturing standards, Improved accessibility and affordability of treatment, these strategic initiatives reinforce Natco?s commitment to advancing healthcare outcomes and addressing critical patient needs across India.
Export Formulations
NATCO has nearly three decades of experience in targeting niche and complex molecules for export markets. This is supported by a global filing strategy that has delivered significant success.
US Market
US Business is one of the strong pillars for the company. With having a front-end access to the market the company also follows a partnership-driven business model in the US for some of the high value or complex products where It leverages its internal research, development and manufacturing strengths, while partners handle litigation and distribution. In FY26, revenue from the US business amounted to INR 23,810 million, compared to INR 31,487 million in FY25.
The Company has 45+ approved Abbreviated New Drug Applications (ANDA) and 25+ Para IVs in the pipeline with 8 tentative approvals
During the year, the company submitted 4 ANDAs and received approval for 5 ANDAs (four tentative approvals and one final approval) from the USFDA.
Canada Market
NATCO Pharma Canada Inc., a wholly owned subsidiary founded in 2012, is headquartered in Toronto. It is supported by local quality assurance, regulatory, and sales teams.
Strong portfolio with 20+ products and pipeline of 20+ pending for launch, including Oncology, Anti-viral, Cardiovascular and CNS therapies
Amongst top 10 generic companies by sales revenue in Canada
Highest market share for Lenalidomide and Oseltamivir
In FY26, revenue was INR 2,517 million.
The subsidiary has more than 20 products approved for the market and 20+ filings in the pipeline. The goal for the subsidiary is to achieve six to eight regulatory filings annually.
Brazil Market
Natcofarma Brasil supplies generic medications for oncology, hematology, cardiology, neurology, and primary care.
Continues to be the single source for Everolimus for the fourth consecutive year
Launched Carfilzomib and Eltrombopag
Oseltamivir continues to perform well
Launched Apixaban in Brazil, amongst the first to launch, through own sales and out-licensing with the highest market share
Out-licensing/ partnering and In-licensing to capture majority market share.
In FY26, revenue was 2,875 million.
The subsidiary continues to file a significant number of products in areas with limited competition.
Asia and other Emerging Markets
NATCO has received approvals from the Health Sciences Authority (HSA) in Singapore for niche oncology formulations. In China, the Company has seen success with Oseltamivir capsules. It has also entered Saudi Arabia and Algeria through government tenders and established a subsidiary in Colombia. Additional presence is maintained in Thailand, Vietnam, Philippines, Indonesia and Australia.
In Rest-of-World (RoW) markets, the portfolio focuses on hepatitis C and anti-cancer formulations, with successful commercialization in countries like Vietnam, Mongolia, Myanmar and Venezuela.
Expanding our footprint in Middle East and
North Africa (MENA)
Participating and winning tenders in Saudi Arabia, Algeria and Egypt and Won tenders in Hong Kong, Ukraine, Algeria, and Thailand
Launched Oseltamivir capsules in China - NATCO?s first product launch in the territory; launched two oncology products Abiraterone & Gefitinib tablets in China
Acquired significant market share for Tenofovir Alafenamide Fumarate in Thailand, Indonesia & Vietnam
Gaining market share in branded generics in oncology by making available basket of products.
APIs
NATCO has developed and commercialised niche APIs for over two decades. The portfolio now covers over fifty Drug Master Files (DMF) and includes treatments for the central nervous system, pain management and cardiovascular care, in addition to its original focus on oncology.
The Company operates two state-of-the-art API manufacturing facilities. Over half of the campus space at these sites is preserved as a Green Belt to support environmental health and safety. These plants have received regulatory clearances from
U.S. Food and Drug Administration (USFDA)
Australias Therapeutic Goods Administration (TGA)
Hamburg Health Authority (Germany)
Japans PMDA
South Koreas KFDA
Mexicos Cofepris
European Directorate for the Quality of Medicines (EDQM)
Crop Health Sciences Division (CHS)
Established in 2019 , the CHS division leverages the Companys techno-legal capabilities and organic chemistry skills. It focuses on providing innovative, green chemistry-based pest and biological crop solutions to help farmers achieve higher yields.
NATCO CHS pioneered the launch of the first pheromone- based mating disrupting product for managing pink bollworm in cotton crops. Moving forward, the division will expand its portfolio to include a broader range of pesticides, insecticides and bio-stimulants for various crops and markets.
Financial Highlights
| Metric | FY 2025 | FY 2026 |
| Total Revenue (INR million) | 47,840 | 43,759 |
| EBITDA (INR million) | 25,505 | 17,341 |
| EBITDA Margin (%) | 53.3% | 39.6% |
| Profit Before Tax (PBT) (Before share of profit of Associate) (INR million) | 22,914 | 14,908 |
| Profit After Tax (PAT) (After share of profit of Associate) (INR million) | 18,834 | 14,185 |
| PAT Margin (After share of profit of associate) (%) | 39.4% | 32.4% |
| Reported EPS (Basic and Diluted) (INR) | 105.26 | 79.20 |
| Networth (INR million) | 76,070 | 92,211 |
| Return on Equity (%) | 24.7% | 15.4% |
| Return on Capital Employed (%) | 30.1% | 16.3% |
SCOT Analysis
f Strengths
Strategic Focus via Demerger: The board-approved demerger of the agrochemicals business (effective October 2026) positions the Company as a pure-play pharmaceutical entity, enabling sharper strategic focus and independent capital allocation. Also increases management bandwidth and focus on the agro business thereby unlocking shareholder value.
Oncology and Specialty Dominance: Strong presence in high-barrier complex generics, with a robust pipeline including GLP-1 agonists (generic Wegovy/Ozempic) and over 20 First-to-File (FTF) Para IV opportunities in the US.
Expanding Global Footprint Acquisition of 49% stake in Adcock Ingram in South Africa.
Elevated R&D and Compliance Costs: Ongoing investment in bioequivalence studies and R&D continue to pressure short-term margins.
Domestic Pricing Pressure: The oncology portfolio remains exposed to price control regulations in India.
Pressure on prices due to government measures to contain drug costs potentially affecting profitability margins
High competitiveness in the generic pharma business demanding relentless innovation to stay ahead in the market.
Regulatory needs to comply across several jurisdictions introducing operational complexity and cost pressures
US Tariffs: Proposed tariffs up to 100% on patented medicines and APIs (April 2026) pose long-term risks. While generics (100% of NATCOs US exports) remain exempt, a one-year review clause introduces policy uncertainty.
Global Supply Chain Volatility: Continued geopolitical disruptions (Middle East and Red Sea) continue to impact freight costs and logistics reliability, posing risks to API supply chains and just-in-time delivery models.
Opportunities
New Trade Partnerships
EU market access (~ $ 572.3 billion) opens significant opportunities across pharmaceuticals and medical technologies.
India-UK Comprehensive Economic and Trade Agreement (CETA) (July 2025) Zero-duty access across 56 pharmaceutical tariff lines, enhancing competitiveness in a key export market.
India-New Zealand FTA (December 2025) Zero-duty access across ~90 tariff lines (earlier up to 5%).
Government-Led Innovation: The Biopharma SHAKTI scheme (H10,000 crore) under Union Budget 2026-27 creates significant funding opportunities for biosimilars and advanced biologics.
Shift to Value-Driven Offerings: Industry transition from volume-led generics to innovation-driven therapies opens up new growth avenues in complex and specialty segments.
Innovative Therapy Areas: Progress in cell and gene therapy, including developments like indigenous bispecific third-generation CAR-T cells, strengthens India?s innovation ecosystem.
Backed by US$2 million in funding from NATCO Pharma, the Company is partnering with CMC Vellore for early-phase clinical trials. This initiative is supported by a robust ecosystem, including CSIR, the Regional Centre for Biotechnology and the Institute of Genomics and Integrative Biology.
US Biosecure Act: As US firms diversify away from Chinese CDMOs, Indian manufacturers like NATCO stand to benefit from increased demand for specialty contract manufacturing.
Risk Management
Please see page no: 36 for details
Cautionary Statement
The statement made in this section describes our objectives, projections, expectation and estimations which may be forward-looking statements? within the meaning of applicable securities laws and regulations. Forward-looking statements are based on certain assumptions and expectations of future events. The Company cannot guarantee that these assumptions and expectations are accurate or will be realised by the Company. Actual result could differ materially from those expressed in the statement or implied due to the influence of external factors which are beyond the control of the Company. The Company assumes no responsibility to publicly amend, modify or revise any forward-looking statements on the basis of any subsequent developments.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.